- A subsidiary of Health Logic Interactive Inc. (CHIP.H) is being acquired by Marizyme Inc.
- The subsidiary, My Health Logic, has a lab-on-chip technology platform and patient-centric digital point-of-care device, MATLOC 1
- The technology is currently being developed to diagnose the three leading biomarkers for chronic kidney disease (CKD)
- Two of My Health Logic’s senior officers, George Kovalyov, CPA, and Harrison Ross, CFA are joining Marizyme in leadership roles
- Health Logic Interactive Inc. (CHIP.H) is unchanged trading at $0.13 per share as of 3:47 p.m. EST
Health Logic Interactive (CHIP.H) subsidiary My Health Logic is being acquired by Marizyme Inc.
The subsidiary, My Health Logic, has a lab-on-chip technology platform and patient-centric digital point-of-care device, MATLOC 1.
Marizyme is actively seeking FDA approval for both MATLOC1 and a second product, DuraGraft.
My Health Logic’s lab-on-chip technology is currently being developed to diagnose the three leading biomarkers for chronic kidney disease (CKD).
By combining the lab-on-chip technology with MATLOC 1 My Health expects to read the two urine biomarkers.
MATLOC 2, the company’s next-generation point-of-care device is designed to assess eGFR using a blood-based biomarker.
eGFR is a key measure of kidney function health and/or stage of kidney disease and is designed to provide a complete quantitative diagnostic assessment for CKD, potentially eliminating the need for lab visits and in-person assessment.
Two of My Health Logic’s senior officers, George Kovalyov, CPA, and Harrison Ross, CFA are joining Marizyme in leadership roles.
George Kovalyov will become Marizyme’s CFO.
Kovalyov is a founding member of the My Health Logic team and is a CPA with cross-border transaction experience.
Before My Health Logic Kovalyov was VP of Finance for Phivida Holdings, a publicly-traded company that raised over $19 million post its IPO and was successfully acquired.
Harrison Ross will become Marizyme’s VP of Finance.
Ross is another founding member of the My Health Logic team and brings extensive knowledge of the MATLOC device and the accompanying lab-on-chip technology.
Health Logic Interactive Inc. (CHIP.H) is unchanged trading at $0.13 per share as of 3:47 p.m. EST.
